What the Repatha TV commercial - The Risk Is Real is about.
Repatha TV Spot, 'The Risk Is Real': A Tale of Hope and Determination
: In a world where heart disease and high cholesterol are all too common, one medication dares to make a difference. Introducing Repatha, a breakthrough treatment that aims to revolutionize the way we approach cardiovascular health.
: Meet Sarah, a woman who understood the dangers that loomed over her due to her high cholesterol levels.
: Sarah made a choice that day, a choice to fight back and take control of her health. She recognized that the risk was real, but so was her potential for a better life.
: Sarah dove headfirst into learning all she could about Repatha. She read about its ability to lower LDL cholesterol levels significantly and reduce the risk of heart attacks and strokes.
: With her doctor's guidance, Sarah incorporated Repatha into her lifestyle. She embraced a healthy diet and regular exercise regimen, fueling her determination to keep heart disease at bay.
: Sarah's story of resilience and hope is a testament to the power of Repatha. This medication, along with lifestyle changes, can help individuals like Sarah reclaim their lives and reduce their risk of heart disease.
: Repatha – because the risk is real, but so is the hope for a brighter, healthier future. Consult your doctor to see if Repatha is right for you.
[Fade out with the Repatha logo and contact information for further inquiries.]
Repatha TV commercial - The Risk Is Real produced for
Repatha
was first shown on television on April 1, 2018.
Frequently Asked Questions about repatha tv spot, 'the risk is real'
Repatha and Praluent are especially expensive because they would be taken for such a long time. Unlike an antibiotic, which patients take for a few days or weeks, those prescribed Repatha would take it for the rest of their lives.
Repatha (evolocumab) is a monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin kexin type 9). PCSK9 is a protein found in the liver that plays a key role in plasma cholesterol metabolism. Once administered it binds to PCSK9 and prevents the circulating PCSK9 from binding to LDL receptors.
Repatha belongs to a class of medications called PCSK9 inhibitors. These drugs help your body remove LDL (“bad”) cholesterol more effectively than it could on its own. They work differently than other drugs used for high cholesterol, such as statins, and have different side effects as well.
Repatha® is an injectable prescription medicine used: in adults with cardiovascular disease to reduce the risk of heart attack, stroke, and certain types of heart surgery.
Doctors prescribe Repatha to treat high cholesterol and lower the risk of cardiovascular problems. But, it can have adverse effects, such as upper respiratory symptoms, high blood pressure, and high glucose levels.
The cost for Repatha (evolocumab) subcutaneous solution (140 mg/mL) is about $258.00 for one of the 140 mg single-use prefilled autoinjectors or a prefilled syringe.
Action. FDA has approved Repatha (evolocumab) injection as an add-on treatment to diet alone or together with certain other therapies for patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH).
“In contrast, the PCSK9 inhibitors did not show any increase in risk of hemorrhagic stroke,” Saver says. The findings suggest that in those patients who have had prior hemorrhagic stroke, PCSK9 inhibitors may be a safer choice for cholesterol management than statins, the authors say.
The most common side effects of Repatha® include: runny nose, sore throat, symptoms of the common cold, flu or flu-like symptoms, back pain, high blood sugar levels (diabetes) and redness, pain, or bruising at the injection site.
Amgen's cholesterol medicine Repatha safe to use in kidney disease patients. Amgen Inc. said its cholesterol-lowering medicine Repatha was safe to use in patients with chronic kidney disease.
Weight gain or weight loss has not been reported as a side effect of Repatha in clinical trials. Monoclonal antibodies, such as Repatha, tend to have few drug interactions and are unlikely to cause liver or kidney damage. No overall differences in safety or efficacy were observed in elderly patients.
Repatha is a medicine that is designed to be taken long term to reduce the risk of cardiovascular disease. Repatha works while you are using Repatha so if you stop taking Repatha, and once all of the Repatha has left your body, then it will stop having its beneficial effect.
